Skip to content

Clinical study on treatment of xanthelasma palpebrarum with ND:YAG picosecond laser

Clinical study on treatment of xanthelasma palpebrarum with ND:YAG picosecond laser

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063203
Enrollment
Unknown
Registered
2022-09-01
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

xanthelasma palpebrarum

Interventions

case series:ND:YAG picosecond laser

Sponsors

Hospital of Dermatology, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, regardless of gender; 2. Fitzpatrick Skin Type II-V; 3. Palpebral xanthoma; 4. Patients who agreed to take photographs of the treatment area during the course of the study; 5. Patients who knew the study well and voluntarily signed the informed consent form before participating in the study, and were able to follow the expected treatment procedure and complete all follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Patients who are sensitive to visible and near-infrared light; 2. Patients with a history of photosensitive epilepsy; 3. Patients whose skin had not returned to normal or whose skin was in a sensitive state before treatment; 4. Patients with squamous-cell carcinoma or melanoma or those with skin cancer in the intended area of treatment; 5. Known cases of coagulopathy or thromboembolism; 6. Patients who have taken or are taking anticoagulants or medications that affect wound healing in the past 6 months; 7. Patients who have taken or are taking drugs known to increase light sensitivity, such as psoralen, in the past 6 months; 8. Patients with a history of immunosuppressive disorders, including HIV infection or AIDS, or who have taken immunosuppressive drug; 9. Patients with active Human herpesvirus 1 (HSV) in the expected treatment area; 10. Patients with active local or systemic infection or open wounds in the area to be treated; 11. Patients who were enrolled in other clinical trials (other than registry studies) within 6 months before screening; 12. Pregnant or lactating patients; 13. The researchers considered that the patients with poor compliance or other organic diseases were not suitable to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
The clearance rate;

Countries

China

Contacts

Public ContactMengli Zhang

Hospital of Dermatology, Chinese Academy of Medical Sciences

zmlhlj@163.com+86 13915998094

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026